Recent Updates
Recently added Catalysts
CERS Positive Sentiment

Cerus Corporation Announces Third Quarter 2026 Financial Results

Key Takeaway: Cerus Corporation reported Q3 2026 financial results on Thursday. CEO Vivek Jayaraman stated the company built on a strong first half of the year. He cited growth in the IFC business and core platelet franchise. The firm also advanced its international INT 200 rollout.

Market Sentiment Analysis

POSITIVE FACTORS

  • Strong performance in Q3 2026 reported.
  • Continued growth in IFC business.
  • Core platelet franchise shows positive trends.
  • International INT 200 rollout is progressing.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~60 mo
Minimal dilution risk
Lead asset
S303 Red Blood Cells
Phase 3 · Focus:Use of S303 RBCs in Patients With Acute Anemia

Full Press Release Details

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today financial results for the third quarter ended September 30, 2026, and provided a business update. "Our solid performance in Q3 builds upon a strong first half of 2026 and increases our confidence as we approach year-end,” said Vivek Jayaraman, Cerus’s president and chief executive officer. “Continued growth from our IFC business, core platelet franchise and international INT 200 rollout strengthens our foundation

Frequently Asked Questions

What were Cerus Corporation's Q3 2026 results?

Cerus reported solid financial performance for Q3 2026.

Who is the CEO of Cerus Corporation?

Vivek Jayaraman is the president and CEO of Cerus.

What business areas contributed to Cerus's growth?

Growth came from the IFC business and core platelet franchise.

What is the INT 200 rollout?

The INT 200 rollout is part of Cerus's international expansion efforts.

Last updated: Nov 2, 2026